8 research outputs found
Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.
Uveal melanoma (UM) is the most common primary intraocular malignancy in the adult eye. Despite the aggressive local management of primary UM, the development of metastases is common with no effective treatment options for metastatic disease. Genetic analysis of UM samples reveals the presence of mutually exclusive activating mutations in the Gq alpha subunits GNAQ and GNA11. One of the key downstream targets of the constitutively active Gq alpha subunits is the protein kinase C (PKC) signaling pathway. Herein, we describe the discovery of darovasertib (NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity. The lead series was optimized for kinase and off target selectivity to afford a compound that is rapidly absorbed and well tolerated in preclinical species. LXS196 is being investigated in the clinic as a monotherapy and in combination with other agents for the treatment of uveal melanoma (UM), including primary UM and metastatic uveal melanoma (MUM)
Fragment-Based Discovery and Structure-Guided Optimization of 2-Benzoyl-7-azabenzimidazoles as Potent, Highly Selective and Orally Active CDK4/6 Inhibitors
Herein we describe the discovery of potent and highly selective inhibitors of both CDK4 and CDK6 via structure-guided optimization of a fragment-based screening hit. CDK6 X-ray crystallography and pharmacokinetic data steered efforts in identifying compound 10 which showed >1000-fold selectivity for CDK4/6 over CDKs 1 and 2 in an enzymatic assay. Furthermore, compound 10 demonstrated in vivo inhibition of pRb-phosphorylation and oral efficacy in a Jeko-1 mouse xenograft model
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
Uveal
melanoma (UM) is the most common primary intraocular malignancy
in the adult eye. Despite the aggressive local management of primary
UM, the development of metastases is common with no effective treatment
options for metastatic disease. Genetic analysis of UM samples reveals
the presence of mutually exclusive activating mutations in the Gq
alpha subunits GNAQ and GNA11. One of the key downstream targets of
the constitutively active Gq alpha subunits is the protein kinase
C (PKC) signaling pathway. Herein, we describe the discovery of darovasertib
(NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity.
The lead series was optimized for kinase and off target selectivity
to afford a compound that is rapidly absorbed and well tolerated in
preclinical species. LXS196 is being investigated in the clinic as
a monotherapy and in combination with other agents for the treatment
of uveal melanoma (UM), including primary UM and metastatic uveal
melanoma (MUM)
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
Uveal
melanoma (UM) is the most common primary intraocular malignancy
in the adult eye. Despite the aggressive local management of primary
UM, the development of metastases is common with no effective treatment
options for metastatic disease. Genetic analysis of UM samples reveals
the presence of mutually exclusive activating mutations in the Gq
alpha subunits GNAQ and GNA11. One of the key downstream targets of
the constitutively active Gq alpha subunits is the protein kinase
C (PKC) signaling pathway. Herein, we describe the discovery of darovasertib
(NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity.
The lead series was optimized for kinase and off target selectivity
to afford a compound that is rapidly absorbed and well tolerated in
preclinical species. LXS196 is being investigated in the clinic as
a monotherapy and in combination with other agents for the treatment
of uveal melanoma (UM), including primary UM and metastatic uveal
melanoma (MUM)
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
Herein, we describe the discovery of potent and highly
selective
inhibitors of both CDK4 and CDK6 via structure-guided optimization
of a fragment-based screening hit. CDK6 X-ray crystallography and
pharmacokinetic data steered efforts in identifying compound <b>6</b>, which showed >1000-fold selectivity for CDK4 over
CDKs 1 and 2 in an enzymatic assay. Furthermore, <b>6</b> demonstrated
in vivo inhibition of pRb-phosphorylation and oral efficacy in a Jeko-1
mouse xenograft model
Ofatumumab versus Teriflunomide in Multiple Sclerosis
BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. METHODS: In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume. RESULTS: Overall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, -0.11; 95% confidence interval [CI], -0.16 to -0.06; P<0.001) and 0.10 and 0.25 in trial 2 (difference, -0.15; 95% CI, -0.20 to -0.09; P<0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; Pâ=â0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; Pâ=â0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; Pâ=â0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups. CONCLUSIONS: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.)